- Key Takeaways
- Spravato REMS billing compliance is a payment prerequisite — a practice must be a REMS-certified healthcare setting, with an enrolled prescriber and enrolled patient, before any dose can be legally administered or reimbursed.
- The FDA-approved Spravato REMS requires three separate enrollments (setting, prescriber, patient), all active before the first dose and maintained on every date of service.
- The ≥2-hour observation is both a clinical and a payment condition; defensible documentation needs explicit start/end times, interval vitals, and a discharge check — not a “patient stable” note.
- REMS gaps cause revenue loss twice: upfront denials and, more damaging, post-payment clawbacks surfaced during audits and prior-authorization renewals.
- Sustained REMS non-compliance can trigger loss of setting certification — ending a practice’s ability to order and bill Spravato entirely.
In fiscal year 2025, the Medicare Fee-for-Service improper payment rate was 6.55 percent, representing $28.83 billion in improper payments. What that headline hides is more useful to a practice than the dollar figure: CMS is consistent that most improper payments are not fraud — they are claims that could not be validated because a required document, signature, or eligibility step was missing. For a therapy like Spravato (esketamine), where every single dose is administered inside a federally restricted program, that distinction is the whole game. The paperwork that proves you followed the rules is the payment.
This is what makes Spravato REMS billing compliance different from ordinary behavioral health billing. A claim can carry a perfect code set and still be indefensible if the practice, the prescriber, or the patient was not properly enrolled and documented under the FDA’s Risk Evaluation and Mitigation Strategy. This guide walks through the compliance side specifically — certification, enrollment, documentation, and the audit exposure that follows a gap. It is written for practice owners, billing managers, and operations leaders standing up or scaling a Spravato program, and it is educational, not legal or coding advice. For the coding mechanics themselves (J0013, G2082/G2083, units), see Neolytix’s 2026 Spravato CPT and HCPCS code guide.
Why REMS means no payment without it?
A REMS is an FDA safety framework required for drugs whose benefits are real but whose risks need active management. Spravato is available only through a restricted distribution program — the Spravato REMS — because of the risks of sedation, dissociation, respiratory depression, and the potential for abuse and misuse. Practically, that means esketamine cannot be picked up at a retail pharmacy or taken home. It can only be dispensed to and administered within a REMS-certified setting.
That restriction is also a payment gate. A payer will not reimburse Spravato administered at a non-certified site, and prior authorization itself assumes REMS eligibility. So the sequence matters: certification and enrollment are not administrative housekeeping you catch up on later — they are the precondition for a billable claim to exist at all. Every downstream step, from prior authorization to clean-claim submission, inherits the compliance status you established up front.
Site and prescriber enrollment steps
The Spravato REMS is built on three separate enrollments, and all three must be in place before a first dose. Missing any one voids the billability of the session, not just the safety of it.
- The healthcare setting must be certified. An outpatient practice enrolls as a certified healthcare setting and designates an authorized representative to complete and oversee that certification. Under the FDA-approved REMS, the certified setting agrees to train relevant staff, monitor each patient for at least two hours after administration, keep the drug from being dispensed for use outside the setting, notify the REMS in advance when a patient’s treatment is transferred to another certified setting, maintain records of every shipment received and every dose dispensed, keep staff-training records, and comply with audits conducted by the manufacturer or a third party acting on its behalf.
- The prescriber must be enrolled. Prescribers complete REMS-specific training on the drug’s risks and the monitoring protocol and attest to those requirements before they can order Spravato through the program.
- The patient must be enrolled individually. Enrollment is a one-time form acknowledging the risks and the monitoring commitment, signed by both patient and provider; the certified setting cannot administer a dose until the patient is enrolled.
Two nuances trip up practices. First, certification is a status you maintain, not a box you check once — both the facility and the prescriber need active certification on the actual date of service, so lapses, staff turnover, or an authorized-representative change can quietly break eligibility. Second, the program is not static: the Spravato REMS was originally approved on March 5, 2019, with its most recent modification approved on October 9, 2025, so the “Spravato REMS requirements” your team trained on a year ago may not match the current program. Assign someone to own re-verification.
- Neolytix • Medical Billing
Medical Billing
The two-hour observation documentation rule
The most operationally demanding — and most audited — REMS requirement is post-administration monitoring. A healthcare provider must monitor each patient on-site for at least two hours after every dose, checking for resolution of sedation, dissociation, and respiratory depression, and tracking heart rate, blood pressure, and respiratory status including pulse oximetry. This does not relax with time — it applies identically on dose one and dose fifty.
For compliance purposes, the rule is only as strong as the record proving it happened. The observation window is simultaneously a clinical safeguard and a payment condition, which is why reviewers scrutinize it. A note that says “patient monitored and stable” is not defensible; a note with explicit start and end times, interval vital signs, and a documented discharge check is. The safest operating principle is to make it impossible for a reviewer to question whether the full window was met.
An audit-proof note template
An audit-ready Spravato record layers REMS-compliance evidence on top of the clinical note. Rather than a free-text summary, capture these fields in a structured, consistent format for every session:
Field | What it proves |
Setting certification status (active on DOS) | The site was legally eligible to administer |
Prescriber REMS enrollment confirmation | The ordering provider was certified |
Patient REMS enrollment on file | The patient was enrolled before dosing |
Diagnosis with supporting severity/history | Medical necessity for the indication |
Dose administered + device count | Ties the clinical record to the billed units |
Observation start and end time | The ≥2-hour window was met |
Interval vitals (BP, HR, pulse oximetry) | Monitoring was performed, not assumed |
Adverse events and interventions | Nothing was omitted from the record |
Discharge readiness check | The patient was cleared appropriately |
Standardizing this — moving from free text to a fixed template — is one of the highest-leverage changes a Spravato program can make, because it removes the ambiguity payers exploit during review. For how these fields map to specific codes and units on the claim, cross-reference the Spravato CPT and HCPCS code guide.
How REMS gaps cause denials and clawbacks
REMS gaps are the most expensive Spravato billing errors precisely because they can hit revenue twice. Up front, an unverified enrollment or missing authorization produces an outright denial. But the more damaging exposure is behind the payment: a claim can be paid, then reversed. Reviewers increasingly cross-reference REMS documentation during retrospective audits and prior-authorization renewals, and when the supporting record is incomplete, a paid claim becomes a recoupment — money the payer takes back. Under federal rules, identified overpayments generally must be reported and returned within 60 days, and audit-triggered recoveries can reach back across prior dates of service, so a single documentation habit can compound across months of sessions.
The tail risk is worse than any one claim. Sustained non-compliance can jeopardize the setting’s certification itself — and losing certification means losing the ability to order and bill the drug at all. Neolytix’s deeper breakdown of these failure modes lives in the Spravato claim denials guide; the takeaway for compliance is that prevention is structural, not clerical. You can see how that plays out in practice in our behavioral health A/R recovery case study.
Your Spravato REMS compliance checklist
Use this as a pre-program and per-session control. Nothing bills until the relevant boxes are checked.
- Healthcare setting certified; authorized representative designated and current
- Setting certification confirmed active on the date of service
- Prescriber REMS training, attestation, and enrollment complete
- Patient enrolled in REMS (form signed by patient and provider) before first dose
- Prior authorization active and expiration tracked (not treated as one-time)
- ≥2-hour observation documented with start/end times and interval vitals
- Dose and device count in the note matches the billed units
- Shipment, dispensing, and staff-training records maintained for audit
- Session record cross-checked against the REMS portal before claim submission
- Someone owns re-verification against current REMS program requirements
Neolytix runs REMS compliance and buy-and-bill revenue cycle as one integrated workstream with enrollment tracking, PA-expiration monitoring, and audit-ready documentation controls, for psychiatric and behavioral health practices across the country. If you’re standing up or scaling a program, our Spravato Billing Services team can map your compliance and denial exposure before it costs you a clawback. For the full operational picture of procurement and in-house-versus-outsource economics, start with the Spravato billing and coding guide, and for what practices actually collect, see the Spravato reimbursement rates breakdown.
- Neolytix • Contact Us
Schedule a Consultation
Neolytix partners with healthcare organizations across revenue cycle, credentialing, and administrative operations ,14+ years of expertise and AI-enabled automation to reduce inefficiencies and drive sustainable growth.
Sources
- U.S. Centers for Medicare & Medicaid Services — Comprehensive Error Rate Testing (CERT), FY2025 improper payment rate: https://www.cms.gov/data-research/monitoring-programs/improper-payment-measurement-programs/comprehensive-error-rate-testing-cert
- U.S. Food & Drug Administration — Spravato (esketamine) REMS approval and modification letter (Drugs@FDA): https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/211243Orig1s027ltr.pdf
- U.S. Centers for Medicare & Medicaid Services — Fiscal Year 2024 Improper Payments Fact Sheet: https://www.cms.gov/newsroom/fact-sheets/fiscal-year-2024-improper-payments-fact-sheet
Frequently Asked Questions
Do you have to be REMS certified to bill for Spravato?
Yes. Spravato is dispensed only through a restricted program, so a practice must be a REMS-certified healthcare setting before it can administer or bill for esketamine. Payers will not reimburse doses given at a non-certified site, which makes certification a payment prerequisite, not an optional compliance step.
Who is the authorized representative in the Spravato REMS program?
The authorized representative is the individual a certified healthcare setting designates to complete and oversee its REMS certification and ongoing obligations. This person is accountable for staff training records, shipment and dispensing logs, and audit readiness, so the role should sit with someone who can maintain the program’s requirements continuously rather than intermittently.
Does Spravato REMS certification expire or need renewing?
Certification is a status a practice must actively maintain, not a one-time credential. Both the setting and the prescriber need current certification on each date of service, and the REMS program is periodically modified — most recently in October 2025 — so practices should re-verify their standing against current requirements rather than assuming prior training still applies.
Can a payer claw back a paid Spravato claim over REMS non-compliance?
Yes. Even a paid Spravato claim can be reversed if a later audit or authorization renewal finds incomplete REMS documentation. Federal rules generally require identified overpayments to be returned within 60 days, and recoveries can reach across prior sessions, so documentation gaps create recoupment exposure well after payment posts.
What happens to a practice's Spravato access if REMS records are incomplete?
Beyond individual claim denials, sustained REMS documentation failures can put the setting’s certification at risk. Because certification is what allows a practice to order and administer esketamine, losing it effectively ends the program — making consistent record-keeping a business-continuity issue, not just a billing one.
